United States Dialysis Market Report by Type, Product & Services, End User, States and Company Analysis, 2026-2034

United States Dialysis Market: Future Outlook, Growth Trends & Forecast (2026–2034)

United States Dialysis Market is expected to reach US$ 44.25 Billion by 2034 from US$ 30.53 Billion in 2025, with a CAGR of 4.21% from 2026 to 2034. The U.S. dialysis market is driven by the growing burden of chronic kidney disease, diabetes, hypertension, and kidney failure, alongside an aging population. Increasing demand for renal replacement therapy, home-based treatment, advanced dialysis technologies, and improved patient monitoring further supports market expansion.

United States Dialysis Industry Landscape

Dialysis is a medical treatment that performs essential kidney functions when the kidneys can no longer adequately remove waste, excess fluids, and certain electrolytes from the blood. The two principal forms are hemodialysis and peritoneal dialysis. Hemodialysis circulates blood through a dialysis machine and filter, whereas peritoneal dialysis uses the patient's peritoneal membrane as a natural filtering surface. Dialysis may be delivered in hospitals, specialized dialysis centers, outpatient facilities, or at home. Treatment can be supported by machines, dialyzers, vascular-access products, dialysis solutions, monitoring systems, and related clinical services. Technological improvements are increasingly focused on treatment quality, convenience, safety, connectivity, and patient independence.

The United States dialysis market is benefiting from the persistent burden of chronic kidney disease and progression to kidney failure requiring renal replacement therapy. Diabetes and hypertension remain important contributors to kidney damage, while population aging increases the number of individuals vulnerable to declining renal function. Demand is also being influenced by the healthcare industry's growing emphasis on home-based and patient-centered treatment. Advances in dialysis machines, remote monitoring, connected technologies, and hemodiafiltration are expanding treatment possibilities.

Recent Breakthroughs Shaping the United States Dialysis Industry

• In September 2024, Baxter International Inc. introduced its next-generation HomeDialysis Pro system, incorporating enhanced connectivity and automated treatment capabilities to improve the convenience and management of home-based dialysis.
• In January 2024, NxStage Medical, a Fresenius Medical Care company, received FDA approval for a portable dialysis device, expanding treatment alternatives for patients seeking greater flexibility and access to home-based renal care.
• In November 2024, DaVita Inc. entered into a strategic collaboration with the American Nephrology Nurses Association (ANNA) to develop comprehensive educational and training programs aimed at strengthening the skills of dialysis healthcare professionals across North America.

Major Growth Drivers Shaping the Future of United States Dialysis Sector

1. Rising Kidney Disease Burden Creates a Broad Treatment Base

The growing prevalence of chronic kidney disease and kidney failure is creating a sustained patient base for the U.S. dialysis market. Kidney disease is closely associated with major chronic conditions such as diabetes and hypertension, while increasing life expectancy means more people are living with conditions that can progressively impair renal function. Once kidney function becomes severely compromised, dialysis or transplantation becomes necessary to sustain life. This creates continuing demand for dialysis machines, dialyzers, vascular-access products, solutions, consumables, and professional services. Healthcare providers are also increasingly emphasizing earlier identification and management of kidney disease, potentially supporting treatment planning before patients reach advanced stages. Meanwhile, nephrology providers are expanding treatment choices across in-center hemodialysis, peritoneal dialysis, and home hemodialysis. This broadening of care models strengthens demand for both conventional and technologically advanced dialysis solutions.

In June 2025, Fresenius Medical Care announced broader U.S. commercialization activities for its 5008X CAREsystem, following FDA clearance, with a full-scale commercial launch planned for 2026. The system supports high-volume hemodiafiltration, representing an important technology development for U.S. dialysis care.

2. Home Dialysis Gains Momentum Through Greater Patient Convenience

The transition toward home-based dialysis is an important structural growth opportunity in the United States. Home dialysis can provide suitable patients with greater flexibility around treatment schedules while reducing the need for frequent travel to dialysis centers. Peritoneal dialysis remains an important home modality, while home hemodialysis is also gaining attention as equipment becomes easier to operate and monitor. Connected devices, remote patient-management platforms, automated treatment systems, and digital monitoring are helping clinicians supervise patients outside traditional facilities. This evolution is encouraging dialysis providers to invest in technologies that combine convenience, treatment reliability, connectivity, and clinical oversight. As patient-centered care becomes more prominent, manufacturers are increasingly developing solutions that support independence while maintaining continuous communication between patients and healthcare professionals.

In February 2026, DaVita announced a partnership with Elara Caring to develop a kidney-specific home-based care model. The initiative is designed to support patients with complex kidney conditions at home, with the objective of improving outcomes and reducing preventable hospitalizations. The partnership demonstrates the increasing focus on extending kidney care beyond traditional dialysis centers.

3. Advanced Dialysis Access Innovations Expand U.S. Treatment Opportunities

Advancements in dialysis vascular-access technology are creating new opportunities in the U.S. dialysis market by addressing one of the critical requirements of long-term hemodialysis treatment. Improved access solutions can help providers manage complications, support treatment continuity, and enhance patient care. Innovation is increasingly focused on developing durable and biologically compatible alternatives to conventional access methods. These technologies can reduce dependence on repeated procedures and potentially improve the experience of patients requiring long-term dialysis. The growing focus on access innovation is also encouraging collaboration between medical-device companies, dialysis providers, and healthcare institutions. As the U.S. dialysis population continues to require reliable long-term treatment, demand for advanced vascular-access products is expected to increase. This trend is broadening market opportunities beyond dialysis machines and consumables toward specialized access technologies, supporting continued innovation across the renal-care ecosystem.

In August 2026, Humacyte reported positive results from its V012 dialysis-access study and announced plans to pursue FDA approval. The development highlights growing interest in advanced biological vascular-access solutions for patients undergoing hemodialysis.

Critical Challenges Facing the United States Dialysis Industry

1. High Treatment Costs and Reimbursement Pressure

Dialysis is a recurring, resource-intensive treatment requiring specialized equipment, consumables, trained healthcare professionals, facility infrastructure, medications, vascular-access management, and continuous monitoring. These requirements create substantial costs for healthcare providers and payers. Dialysis organizations must balance clinical quality with operational efficiency, particularly as reimbursement policies and payer arrangements continue to influence treatment economics. Home dialysis can reduce certain facility-related expenses, but it requires patient training, equipment installation, supply delivery, technical assistance, and ongoing clinical supervision. Advanced technologies such as connected machines and high-volume hemodiafiltration can also involve additional investment. Smaller providers may face greater difficulties in upgrading equipment or establishing comprehensive home-treatment programs. Consequently, manufacturers must demonstrate meaningful clinical and operational value while dialysis providers increasingly focus on cost management, utilization efficiency, supply-chain reliability, and long-term treatment outcomes.

2. Patient Adherence, Workforce Requirements, and Clinical Complexity

Dialysis requires consistent and repeated treatment, making patient adherence a major challenge for providers. Patients may experience fatigue, dietary restrictions, transportation difficulties, treatment-related discomfort, or challenges adapting to complex home procedures. Home dialysis requires additional education and patient or caregiver involvement, which can restrict suitability for some individuals. At the same time, dialysis providers require skilled nurses, technicians, nephrologists, and other specialists to operate equipment, monitor patients, manage complications, and maintain treatment quality. Workforce shortages can increase operational pressure and limit expansion of services. Advanced treatment technologies can also require additional training and clinical familiarity. Therefore, market participants must invest not only in machines and consumables but also in patient education, workforce development, remote monitoring, technical support, and simplified treatment interfaces to improve adherence and maintain high-quality care.

California — Technology, Population Scale, and Advanced Kidney Care

California represents a highly attractive market for dialysis providers and equipment manufacturers because of its large population, extensive healthcare infrastructure, and concentration of advanced medical centers. The state includes major metropolitan healthcare clusters such as Los Angeles, San Francisco, San Diego, and Sacramento, where nephrology specialists, hospitals, dialysis organizations, and outpatient facilities support a broad renal-care ecosystem. California's technology-oriented environment also provides opportunities for connected dialysis equipment, remote monitoring, home-treatment platforms, and digital patient-management solutions. The state's diverse population creates demand for flexible treatment models capable of addressing different patient needs and socioeconomic circumstances. Home dialysis can offer additional convenience for suitable patients, while large dialysis centers continue to serve patients requiring facility-based treatment. Manufacturers can strengthen their presence through partnerships with healthcare systems, clinical research institutions, nephrologists, and outpatient providers. California's combination of healthcare sophistication and demographic scale makes it a major strategic market for dialysis technologies.

Texas — A Vast Healthcare Network Drives Dialysis Opportunities

Texas offers substantial opportunities for dialysis market expansion because of its large population, extensive hospital network, and rapidly developing healthcare infrastructure. Major metropolitan areas including Houston, Dallas–Fort Worth, Austin, and San Antonio contain numerous hospitals, specialty practices, dialysis centers, and ambulatory healthcare providers. The state's broad geographic footprint also creates demand for treatment models capable of serving patients outside major urban centers. Home dialysis technologies can be particularly relevant where transportation to dialysis facilities presents challenges. At the same time, large metropolitan healthcare systems provide opportunities for advanced hemodialysis equipment, high-volume hemodiafiltration, connected monitoring, and specialized nephrology services. Diabetes, hypertension, cardiovascular disease, and other chronic conditions remain important areas of healthcare management, supporting continuing attention to kidney health. Providers are therefore likely to seek equipment that improves workflow efficiency while manufacturers can target Texas through physician education, provider partnerships, home-dialysis programs, and technology demonstrations.

New York — Dense Medical Infrastructure Supports Sophisticated Renal Care

New York represents an important dialysis market because of its dense network of hospitals, academic medical centers, specialist physicians, and outpatient healthcare facilities. New York City provides a particularly concentrated environment for advanced nephrology services, clinical research, and adoption of innovative medical technologies. The state also has substantial demand for chronic disease management, creating opportunities for dialysis providers and manufacturers to strengthen early kidney-disease intervention and treatment pathways. Home dialysis solutions can support patients seeking greater treatment flexibility, while in-center services remain essential for patients who require facility-based care. Advanced dialysis systems, remote monitoring, automated peritoneal dialysis equipment, and next-generation hemodialysis platforms can benefit from the state's sophisticated clinical environment. Academic institutions may also contribute to clinical research and technology evaluation. Market participants can capitalize on these opportunities through partnerships with healthcare systems, physician training, patient education, and investments in digitally connected renal-care solutions.

Florida — An Aging Population Creates a Strong Renal-Care Opportunity

Florida is a significant U.S. dialysis market because of its large older-adult population and extensive healthcare infrastructure. Aging is associated with a greater risk of chronic diseases that can contribute to declining kidney function, increasing the need for nephrology services and renal replacement therapy. Major population centers such as Miami, Tampa, Orlando, and Jacksonville provide large healthcare markets with hospitals, specialty providers, dialysis facilities, and outpatient care networks. Florida's geographic characteristics also create opportunities for home dialysis, which can provide greater convenience for suitable patients and reduce dependence on frequent facility visits. Dialysis providers are increasingly evaluating technologies that support remote monitoring, automated treatments, and patient-centered care. Manufacturers can also benefit from partnerships with senior-care networks, hospitals, nephrology practices, and home healthcare providers. As demand for chronic disease management continues, Florida's demographic structure and healthcare capacity should make it an important market for dialysis equipment, consumables, and services.

United States Peritoneal Dialysis Market — Home-Based Therapy Expands Patient Choice

The United States peritoneal dialysis market is supported by growing interest in home-based renal replacement therapy and treatment models that provide greater flexibility to suitable patients. Peritoneal dialysis uses the patient's peritoneal membrane to remove waste and excess fluid and can be performed at home with manual exchanges or automated cycling systems. Baxter has been a major participant in the U.S. home dialysis ecosystem, providing peritoneal dialysis products, automated cyclers, supplies, patient support, and remote-management technologies. Technological improvements are making automated treatment easier to manage while remote connectivity allows healthcare teams to monitor treatment information. Demand is also supported by efforts to increase patient awareness of home therapies. However, patient selection, training, caregiver involvement, infection management, supply logistics, and adherence remain important factors affecting adoption. The segment is therefore increasingly focused on combining convenience with clinical support.

United States Dialysis Services Market — Integrated Care Models Reshape Renal Treatment

The U.S. dialysis services market encompasses in-center hemodialysis, home dialysis support, clinical monitoring, patient education, vascular-access management, laboratory services, medication coordination, and other renal-care activities. Demand remains closely connected to the continuing need for kidney replacement therapy among patients with advanced kidney failure. Large dialysis providers operate extensive networks of treatment facilities, while hospitals and independent centers contribute to the broader care ecosystem. The market is gradually evolving toward more patient-centered models, including home treatment, remote monitoring, and technology-enabled care coordination. Providers are also investing in treatment efficiency and advanced modalities to improve clinical outcomes. Fresenius Medical Care's BEACON-US initiative announced in July 2026 illustrates the industry's increasing emphasis on generating real-world evidence for advanced dialysis therapies in routine U.S. practice. Competition increasingly centers on treatment quality, patient experience, operational efficiency, technology, accessibility, and the ability to provide coordinated long-term renal care.

United States Home Dialysis Market — Connected Technologies Bring Treatment Closer to Patients

The U.S. home dialysis market is gaining importance as healthcare providers seek treatment models that give appropriate patients greater flexibility and independence. Home dialysis primarily includes peritoneal dialysis and home hemodialysis. Automated equipment, remote monitoring, digital connectivity, and simplified interfaces are helping healthcare teams supervise treatment outside traditional dialysis facilities. Baxter's established home-dialysis infrastructure includes peritoneal dialysis products, technical support, supply delivery, and remote patient-management capabilities, demonstrating the importance of integrated support ecosystems for home treatment. The market can also benefit from efforts to educate patients and clinicians about home therapy options. However, successful adoption requires suitable home environments, patient training, reliable supply chains, caregiver support when needed, and ongoing clinical supervision. Future growth is likely to depend on technologies that improve usability, connectivity, safety, and treatment personalization while reducing the practical burden associated with home-based renal replacement therapy.

Research Methodology of the United States Dialysis Market

1. Market Definition and Scope

• Defined the market by assessing revenues generated from dialysis treatments, equipment, consumables, and related products used to treat kidney failure in the United States.
• Included hemodialysis, peritoneal dialysis, dialysis machines, dialyzers, bloodlines, dialysis concentrates, dialysate, and other relevant supplies according to the selected scope.
• Evaluated dialysis services provided through in-center facilities, hospitals, and home-based treatment settings.
• Distinguished service revenue from equipment and product sales to prevent double counting, particularly when dialysis treatment payments included consumables.

2. Bottom-Up Market Estimation

• Estimated the market by calculating revenue generated from dialysis services, equipment, consumables, and other included categories.
• Identified the number of patients receiving dialysis and assessed their treatment frequency, modality, and annual expenditure.
• Estimated service revenue using annual treatment volumes and average revenue per treatment.
• Calculated equipment and consumable revenue separately where these sales were not already included in dialysis service payments.

Bottom-Up Formula:

• Total Market Size = Dialysis Service Revenue + Equipment Revenue + Consumables Revenue + Other Included Revenue
• Dialysis service revenue was calculated using the number of treatments multiplied by average revenue per treatment.
• Equipment revenue was estimated using units sold multiplied by average selling prices.
• Consumable revenue was calculated using units consumed multiplied by average selling prices, excluding products already counted within bundled service revenue.
• Validated estimates using company disclosures, patient statistics, facility data, treatment utilization, and pricing information.

3. Top-Down Market Estimation

• Examined broader U.S. kidney care expenditure, end-stage renal disease (ESRD) treatment spending, dialysis-related healthcare expenditure, and relevant medical equipment sales.
• Identified the portion attributable specifically to dialysis services, equipment, and consumables included in the market scope.
• Reviewed healthcare expenditure statistics, Medicare reimbursement information, claims data, industry reports, and company financial disclosures.
• Separated dialysis expenditure from kidney transplantation, general nephrology consultations, unrelated hospital services, and other excluded kidney care costs.

Top-Down Formula:

• Dialysis Market Size = Relevant Addressable Kidney Care Expenditure × Dialysis-Specific Revenue Share
• Defined the addressable expenditure according to the selected market scope.
• Derived the dialysis-specific share from treatment utilization, claims data, service revenue, and relevant product sales.
• Compared the top-down estimate with the bottom-up calculation and investigated differences in coverage, reimbursement, and revenue attribution.

4. Patient Population Analysis

• Examined the incidence and prevalence of end-stage renal disease and the number of patients receiving dialysis in the United States.
• Used the United States Renal Data System (USRDS), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and Centers for Medicare & Medicaid Services (CMS) as key sources.
• Distinguished newly diagnosed ESRD patients from the existing dialysis population.
• Considered patient mortality, kidney transplantation, treatment initiation, and changes in dialysis modality when estimating the active patient base.
• Avoided counting patients receiving temporary dialysis as long-term patients without appropriate adjustments.

5. Segmentation by Dialysis Type

• Divided the market into hemodialysis and peritoneal dialysis.
• Further categorized hemodialysis into in-center hemodialysis and home hemodialysis.
• Assessed peritoneal dialysis through relevant treatment approaches, including continuous ambulatory peritoneal dialysis and automated peritoneal dialysis.
• Estimated revenue for each modality using patient volumes, treatment frequency, equipment requirements, consumable usage, and average treatment costs.
• Considered differences in service delivery and supply requirements between facility-based and home-based treatment.

6. Dialysis Services Revenue Analysis

• Evaluated revenue generated by outpatient dialysis centers, hospital-based dialysis units, and home dialysis service providers.
• Estimated in-center hemodialysis revenue using annual treatment sessions and average revenue per session.
• Assessed peritoneal dialysis and home hemodialysis using active patients, annual treatment expenditure, and applicable reimbursement rates.
• Examined the effects of payer mix, treatment duration, reimbursement arrangements, and facility utilization on service revenue.
• Distinguished dialysis provider revenue from the separate sales of equipment and consumables to avoid double counting.

7. Segmentation by Equipment and Consumables

• Categorized equipment into hemodialysis machines, peritoneal dialysis cyclers, water treatment systems, and other relevant dialysis equipment.
• Included consumables such as dialyzers, blood tubing, filters, dialysis concentrates, dialysate solutions, catheters, and relevant treatment supplies.
• Estimated equipment revenue using annual shipments, replacement demand, installed base, and average selling prices.
• Calculated consumable revenue using patient volumes, treatment frequency, product utilization, and average prices.
• Evaluated equipment replacement cycles and demand from newly established or expanded dialysis facilities.

8. Segmentation by Care Setting and Distribution Channel

• Analyzed dialysis treatment delivered through independent dialysis centers, hospital facilities, and home-based care.
• Examined equipment and consumable distribution through manufacturers, medical supply distributors, hospitals, dialysis providers, and other relevant channels.
• Assessed differences in procurement, product purchasing, and service delivery across care settings.
• Used CMS dialysis-facility datasets to evaluate facility coverage and relevant treatment measures.
• Eliminated overlapping revenue between manufacturers, distributors, and healthcare providers wherever the market valuation required a single point in the supply chain.

9. Pricing and Reimbursement Analysis

• Reviewed Medicare reimbursement policies, commercial insurance arrangements, treatment costs, and available provider revenue information.
• Evaluated average revenue per hemodialysis session and annual expenditure associated with peritoneal dialysis and home treatment.
• Assessed differences in reimbursement by modality, treatment setting, and payer category.
• Examined the effects of bundled payment arrangements, operating costs, and changes in reimbursement on dialysis service revenue.
• Distinguished provider reimbursement from manufacturer revenue when estimating the total market.

10. Company Revenue and Competitive Landscape

• Reviewed annual reports, investor presentations, regulatory filings, and product disclosures from dialysis service providers and medical device manufacturers.
• Evaluated major dialysis service providers, including DaVita and Fresenius Medical Care, alongside relevant equipment and consumable manufacturers such as Baxter, Nipro, B. Braun, and other market participants.
• Examined company revenues, dialysis patient volumes, treatment-center networks, product sales, equipment launches, and expansion activities.
• Allocated only the revenue attributable to dialysis-related operations and products included in the defined market.
• Avoided adding consolidated company revenue when it included unrelated medical products or services.

11. Primary and Secondary Research

• Collected secondary information from USRDS, NIDDK, CMS, Medicare reimbursement publications, company reports, regulatory disclosures, and clinical literature.
• Conducted primary research with nephrologists, dialysis center operators, hospital administrators, equipment manufacturers, medical supply distributors, and industry experts.
• Validated assumptions regarding patient numbers, treatment frequency, reimbursement, equipment demand, consumable utilization, and service costs.
• Compared primary and secondary research findings to refine the estimates.

12. Market Forecasting

• Forecast market revenue by projecting dialysis patient numbers, treatment volumes, modality adoption, equipment demand, and consumable usage.
• Considered ESRD prevalence, diabetes and hypertension trends, population aging, kidney transplantation, and changes in home dialysis utilization.
• Evaluated the effects of reimbursement policies, facility expansion, equipment replacement, technological improvements, and home-based treatment adoption.
• Prepared separate forecasts for dialysis services, equipment, and consumables before consolidating the total market.
• Validated forecasts against historical trends, company developments, and available healthcare expenditure projections.

13. Market Reconciliation and Validation

• Compared bottom-up estimates with top-down calculations to identify discrepancies in market size.
• Investigated differences arising from patient counts, treatment frequency, reimbursement rates, product pricing, and market scope.
• Cross-checked service revenue against provider disclosures and equipment or consumable revenue against manufacturer information.
• Eliminated duplicate revenue from bundled treatment payments and separately reported product sales.
• Finalized the market estimate after reconciling both approaches using the available evidence.

Overall Market Estimation Framework

1. Defined the market scope, including services, equipment, and consumables.
2. Estimated the dialysis patient population using official ESRD statistics.
3. Calculated dialysis service revenue from treatment volumes and average reimbursement or revenue per treatment.
4. Estimated equipment and consumable sales separately, excluding revenue already captured in bundled services.
5. Applied the top-down approach to validate the estimate against broader kidney care expenditure and dialysis-specific revenue.
6. Segmented the market by dialysis modality, care setting, equipment, and consumables.
7. Validated estimates using company disclosures, CMS data, USRDS statistics, and industry interviews.
8. Reconciled both approaches and forecast future market revenue.

Core Market Formula:

• United States Dialysis Market = Dialysis Service Revenue + Dialysis Equipment Revenue + Dialysis Consumables Revenue + Other Included Revenue
• Bottom-Up Approach: Sum of dialysis treatment revenue, equipment sales, and consumable sales, calculated separately without overlapping revenue.
• Top-Down Approach: Relevant kidney care expenditure multiplied by the evidence-based share attributable to dialysis.

Important consideration: The final market size depended on whether the study covered dialysis services alone or the broader dialysis ecosystem, including equipment and consumables. The same scope and revenue-recognition basis were maintained across both estimation approaches.

Market Segmentation

Type

• Peritoneal Dialysis
• Hemodialysis

Product & Services

• Services
• Equipment
• Consumables
• Drugs

End User

• Home Dialysis
• In Center Dialysis

Top States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All Key Players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

1. Asahi Kasei Corporation
2. B. Braun Melsungen AG
3. Baxter International Inc.
4. Becton Dickinson and Company
5. DaVita Inc.
6. Fresenius Medical Care AG & Co. KGaA
7. JMS Co.Ltd.
8. Medtronic Plc.

Report Details: